


## Product Introduction

### Bardoxolone Methyl

Bardoxolone Methyl is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities. Phase 3.

#### Technical Data:

<b>Molecular Weight (MW):</b>	505.69	
<b>Formula:</b>	C <sub>32</sub> H <sub>43</sub> NO <sub>4</sub>	
<b>Solubility (25°C)</b>	DMSO 21 mg/mL	
<b>* &lt;1 mg/ml means slightly soluble or insoluble:</b>	Water <1 mg/mL	
	Ethanol <1 mg/mL	
<b>Purity:</b>	>98%	
<b>Storage:</b>	3 years -20°C Powder	
	6 months-80°C in DMSO	
<b>CAS No.:</b>	218600-53-4	

#### Biological Activity

Bardoxolone Methyl exhibits potent inhibitory activities against production of nitric oxide induced by interferon- $\gamma$  in mouse macrophages with IC<sub>50</sub> of 0.1 nM. <sup>[1]</sup> Bardoxolone Methyl decreases the viability of leukemic HL-60, KG-1, and NB4 cells with IC<sub>50</sub> of 0.4, 0.4, and 0.27  $\mu$ M, respectively. CDDO-Me induces pro-apoptotic Bax protein, inhibits the activation of ERK1/2, and it blocks Bcl-2 phosphorylation, which contributes to the induction of apoptosis. <sup>[2]</sup> Bardoxolone Methyl potently inhibits both constitutive and inducible NF-kappaB activated by TNF, interleukin (IL)-1beta, phorbol ester, okadaic acid, hydrogen

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

peroxide, lipopolysaccharide, and cigarette smoke. [3]

Bardoxolone Methyl (60 mg/kg) reduces the number, size, and severity of lung tumors in vivo. [4]

Bardoxolone Methyl significantly reduces the in vivo inflammatory cytokine response following LPS challenge, induces HO-1 protein expression in the spleen, and protects mice against lethal-dose LPS. [5]

The only IKK $\beta$  inhibitor in clinical use for solid tumors, type 2 diabetes, and chronic kidney disease. An orally-available antioxidant inflammation modulator.

## References

[1] Honda T, et al. J Med Chem. 2000, 43(22), 4233-4246.

[2] Konopleva M, et al. Blood. 2002, 99(1), 326-335.

[3] Shishodia S, et al. Clin Cancer Res. 2006, 12(6), 1828-1838.

[4] Liby K, et al. Cancer Res. 2007, 67(6), 2414-2419.

[5] Auletta JJ, et al. J Interferon Cytokine Res. 2010, 30(7), 497-508.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.